ZBIO - NASDAQ
Zenas BioPharma, Inc.
$17.13
+1.6%Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
At a Glance
Live SnapshotZenas BioPharma, Inc. Management Team
Ms. Jennifer A. Fox
Chief Business Officer & Chief Financial Officer
Compensation
$856,021
Mr. Orlando Oliveira
Chief Commercial Officer
Compensation
$509,897
Mr. Leon Oliver Moulder Jr., M.B.A.
Chief Executive Officer & Chairman of the Board
Compensation
$686,554
Ms. Caroline Chevalier
Chief Human Resources Officer
Mr. Jeffrey Held
Chief Legal Officer
Mr. Joseph L. Farmer
Chief Operating Officer & President
Compensation
$757,454
Dr. Haley Laken Ph.D.
Chief Scientific Officer
Dr. Lisa von Moltke M.D.
Head of Research & Development and Chief Medical Officer
Dr. Tanya Z. Fischer M.D., Ph.D.
Head of Research & Development and Chief Medical Officer.
Compensation
$332,542
Zenas BioPharma, Inc. Insider Positioning
During the last 12 months, insiders have purchased $13.56M worth of ZBIO shares, with no selling activity reported.
3 Months
402.8K
7.67M
0
0.00
+7.7M
+$7.67M
3-6 Months
192.1K
3.49M
0
0.00
+3.5M
+$3.49M
6-9 Months
126.3K
2.40M
0
0.00
+2.4M
+$2.40M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Moulder Leon O Jr
Director, Officer: Chief Executive Officer
$5.76M
Fairmount Funds Management Llc
Director
$3.00M
Lu Hongbo
Director
$2.15M
Nunn Jason Raleigh
Director
$1.20M
Sr One Capital Management, Llc
10 Percent Owner
$1.20M
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $13.56M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
ZBIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 16, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 10, 2025 | 2025 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.